Voges, Alessandra Rinah Nogueira; Ubukata, Rodrigo; Yazbek, Karina Velloso Braga; Caballero, Otávia Luisa; Salazar, Andres Mario; Massoco, Cristina de Oliveira 
; Dagli, Maria Lúcia Zaidan
Source: Cancers. Unidade: FMVZ
Subjects: CÃES, ANTIVIRAIS, IMUNOTERAPIA, NEOPLASIAS EM ANIMAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VOGES, Alessandra Rinah Nogueira et al. Intratumoral (Poly-ICLC) therapy for dogs with advanced cancers: first report on clinical effectiveness, quality of life, and adverse events. Cancers, v. 13, n. 9, p. 1-11, 2021Tradução . . Disponível em: https://doi.org/10.3390/cancers13092237. Acesso em: 03 nov. 2024.APA
Voges, A. R. N., Ubukata, R., Yazbek, K. V. B., Caballero, O. L., Salazar, A. M., Massoco, C. de O., & Dagli, M. L. Z. (2021). Intratumoral (Poly-ICLC) therapy for dogs with advanced cancers: first report on clinical effectiveness, quality of life, and adverse events. Cancers, 13( 9), 1-11. doi:10.3390/cancers13092237NLM
Voges ARN, Ubukata R, Yazbek KVB, Caballero OL, Salazar AM, Massoco C de O, Dagli MLZ. Intratumoral (Poly-ICLC) therapy for dogs with advanced cancers: first report on clinical effectiveness, quality of life, and adverse events [Internet]. Cancers. 2021 ; 13( 9): 1-11.[citado 2024 nov. 03 ] Available from: https://doi.org/10.3390/cancers13092237Vancouver
Voges ARN, Ubukata R, Yazbek KVB, Caballero OL, Salazar AM, Massoco C de O, Dagli MLZ. Intratumoral (Poly-ICLC) therapy for dogs with advanced cancers: first report on clinical effectiveness, quality of life, and adverse events [Internet]. Cancers. 2021 ; 13( 9): 1-11.[citado 2024 nov. 03 ] Available from: https://doi.org/10.3390/cancers13092237
